secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2023-10-23T23:59:59+00:00
Accession:  0001104659-23-110788
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

NRX Pharmaceuticals receives Nasdaq delisting notice for bid price non-compliance; plans hearing
--------------------------------------------------------------------------------

- Received Nasdaq delisting notice Oct 17, 2023 for failing minimum bid price rule (closing bid <$1 for 30 days).
- Plans to request hearing before Nasdaq Hearings Panel; hearing request will stay delisting pending decision.
- Initial 180-day compliance period expired Oct 16, 2023 without regaining compliance.
- Identifies four potential positive business developments that could affect share price, including NRX-101 trial data and milestone.
- No assurance of Panel decision or ability to regain listing compliance within any extension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923110788/0001104659-23-110788-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923110788/tm2328933d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-110788

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer